The global fractional flow reserve market to grow at a CAGR of 14.14% during the period 2016-2020.
Global Fractional Flow Reserve Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
A trend which is propelling market growth is the rising number of clinical trials and regulatory approvals. There has been a growing trend of clinical trials and regulatory approvals in the market. With the growing demand for fractional flow reserve technology, the new companies are continuously seeking ways to gain approvals and launch new products in the market to improve their market share. In January 2014, ACIST's RXi received 510(k) FDA approval for use in gaining intravascular pressure measurements in the diagnosis and treatment of peripheral artery disease and CAD.
According to the report, a key growth driver is the increased need for diagnosis of coronary artery diseases (CAD). There has been an increased need for a suitable procedure to diagnose the growing prevalence of CAD. Coronary angiography is the standard procedure used for diagnosis of CAD. However, the standard coronary angiography with visual assessment and quantitative coronary angiography alone cannot accurately predict the exact lesion that is causing ischemia.
These methods may not provide the clear picture about the severity and hemodynamic significance of lesions. Several studies state that the coronary angiogram is limited and does not measure the extent to which a stenosis is hampering the blood flow. Therefore, the demand for new diagnosis techniques such as fractional flow reserve has increased.
Further, the report states that one challenge that could impact market growth adversely is the stringent regulatory environment.